The Institute for Clinical and Economic Review (aka ICER) recently released their Draft Evidence report for Arthritis therapies. This report isn’t an independent review. It is a document of discrimination. It takes a direct aim at the most vulnerable patients, their families and loved ones. We are calling on everyone in the Arthritis community to make their voices heard.
This webinar will show you how.
In this 30 minute webinar we spoke with health economist, Paul Langley, Ph.D., our lead research advisor for the Institute for Patient Access & Affordability, a program of Patients Rising. Dr. Langley walked us through the ICER methodology, and why, in his opinion — it should not be used to determine your treatment access.
We also were happy to have Anna Legassie share her insights with us. Anna is an athlete, patient advocate, and strategy manager living in Boston. She was diagnosed with Systemic Juvenile Idiopathic Arthritis (SJIA) twenty-five years ago at age 11, and today she lives with rheumatoid arthritis and recurrent pericarditis. She is on the Massachusetts Leadership Board of the Arthritis Foundation and also serves on the Foundation’s National Advocacy Committee.